Data Bytes: taking stock of Biogen’s pipeline as aducanumab timeline comes into focus

As its high-profile Alzheimer’s candidate aducanumab has inched toward the finish line, Biogen has been diversifying its neurology portfolio beyond the high-risk indication. The biotech has built a pipeline of 26 clinical assets spanning 15 indications and five modalities.

FDA granted Priority Review to aducanumab on Friday, giving it a March 7, 2021, PDUFA date, and stated that “if possible, it plans to act early on this application under an expedited review.” Biogen Inc. (NASDAQ:BIIB) said it did not use a Priority Review voucher for the BLA...